Showing results (201-210 of 931) with videos related to

Sort By:
Pageof 94
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic LeukemiaJayastu Senapati, Hagop Kantarjian, Fadi G Haddad, et al.
Blood|December 12, 2018
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemiaJan A Burger, Mariela Sivina, Nitin Jain, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Progress in acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Susan O'Brien, et al.
Cancer|April 25, 2003
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experienceGuillermo Lazo, Hagop Kantarjian, Elihu Estey, et al.
Expert Review of Anticancer Therapy|December 22, 2007
Targeted therapy in chronic myeloid leukemiaElias Jabbour, Jorge E Cortes, Hady Ghanem, et al.
Current Oncology Reports|June 7, 2012
Philadelphia-positive acute lymphoblastic leukemia: current treatment optionsTheresa Liu-Dumlao, Hagop Kantarjian, Deborah A Thomas, et al.
Cancer|September 2, 2005
Mature T-cell leukemiasFarhad Ravandi, Hagop Kantarjian, Dan Jones, et al.
Expert Opinion on Biological Therapy|March 17, 2015
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomasMaro Ohanian, Hagop Kantarjian, Daniel Guy, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studiesHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Blood|March 18, 2006
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemiaKensuke Kojima, Marina Konopleva, Teresa McQueen, et al.
Pageof 94